Jubilant Ingrevia consolidated Q1 FY2024 PAT up QoQ at Rs. 57.59 Cr
Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023
Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023
Apollo Transplant program is the first program in India to cross the landmark of 18500 kidney transplants, 4300 liver transplants and 500 pediatric liver transplants
CMOs showed an increasing reluctance to take on debt in 2022
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Subscribe To Our Newsletter & Stay Updated